Physician profile
Leo E Orr
NPI 1730102286
$19,024.66
in general payments reported to CMS, 2019-2025
73 companies · $3,554 in 2025
The $3,554 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,479 · 2020: $1,433 · 2021: $2,285 · 2022: $3,153 · 2023: $3,251 · 2024: $3,869 · 2025: $3,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,475.11 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,709.75 | 2019-2025 | Erleada, Akeega, Balversa |
| Novartis Pharmaceuticals Corporation | $1,522.36 | 2019-2025 | |
| Pfizer INC. | $1,363.26 | 2019-2025 | |
| Exelixis INC. | $1,046.41 | 2020-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $837.85 | 2019-2025 | Opdivo, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $765.72 | 2019-2024 | |
| Incyte Corporation | $742.99 | 2020-2025 | Jakafi, Monjuvi, Zynyz |
| Eisai INC. | $696.54 | 2019-2025 | |
| Genzyme Corporation | $678.83 | 2019-2025 | |
| Glaxosmithkline, LLC. | $642.32 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $625.14 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $563.74 | 2022-2025 | Enhertu |
| Astellas Pharma US INC | $530.71 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Celgene Corporation | $485.49 | 2019-2025 | Reblozyl, Opdualag |
| Sobi, INC | $460.27 | 2022-2025 |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.